Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.
Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.
Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.
After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.
Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.
Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.
Expert hematologist/oncologists share their perspectives on use of biomarkers to help prognosticate graft vs host disease.
Alexis A. Thompson, MD, MPH, reviewed the unmet needs of patients with β-thalassemia who will receive betibeglogene autotemcel.
Pemigatinib had been approved by the FDA as a treatment for patients with FGFR1 rearranged relapsed/refractory myeloid/lymphoid neoplasms.
Based on results of the phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for pediatric patients with chronic graft-versus-host disease.